Janux Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
JANX$12.76-27.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and par value data)
| December 31, | ||
|---|---|---|
| Assets | 2025 | 2024 |
| Current assets: | ||
| Cash and cash equivalents | $52,334 | $430,605 |
| Short-term investments | 914,233 | 594,568 |
| Prepaid expenses and other current assets | 9,320 | 8,493 |
| Total current assets | 975,887 | 1,033,666 |
| Restricted cash | 816 | 816 |
| Property and equipment, net | 3,852 | 4,864 |
| Operating lease right-of-use assets | 18,402 | 19,286 |
| Other long-term assets | 2,608 | 2,884 |
| Total assets | $1,001,565 | $1,061,516 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,971 | $4,026 |
| Accrued expenses | 17,633 | 11,684 |
| Current portion of operating lease liabilities | 2,393 | 1,749 |
| Total current liabilities | 24,997 | 17,459 |
| Operating lease liabilities, net of current portion | 19,746 | 21,276 |
| Total liabilities | 44,743 | 38,735 |
| Commitments and contingencies (Note 3) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; authorized shares – 10,000,000 at December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value; authorized shares – 200,000,000 at December 31, 2025 and 2024, respectively; issued shares – 60,384,283 and 59,064,606 at December 31, 2025 and 2024, respectively; outstanding shares – 60,384,283 and 59,064,606 at December 31, 2025 and 2024, respectively | 60 | 59 |
| Additional paid-in capital | 1,303,828 | 1,258,316 |
| Accumulated other comprehensive income | 4,316 | 2,163 |
| Accumulated deficit | (351,382) | (237,757) |
| Total stockholders’ equity | 956,822 | 1,022,781 |
| Total liabilities and stockholders’ equity | $1,001,565 | $1,061,516 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.